Conferences

Coverage from professional conferences on research relevant to pancreatic cancer.

Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer
Presenter: C. C. HsuPresenter's Affiliation: Johns Hopkins Hospital, Baltimore, MDType of Session: ScientificBackground Despite aggressive multimodality treatment, pancreatic cancer is associated with a high rate of mortality. Even the 15-20% of patients who present with resectable disease experience 5-year survivals of only 10-25%.

A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative oncology Group (ECOG) trial
Presenter: J. Berlin Affiliation: ECOG, USA Background: The vast majority of patients with pancreatic cancer are diagnosed with locally advanced unrespectable or advanced disease for which there is no curative therapy. Many chemotherapeutic agents have been evaluated in patients with pancreatic cancer. Gemcitabine (gem) and 5-FU are the

Gemcitabine-Oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): a Gercor Multicenter phase II study
Presenter: C. Louvet Affiliation: Hospital St-Antoine, Paris France Background: Gemcitabine has been shown to be an active agent in the treatment of pancreatic cancer. Some preclinical data showed that the combination of gemcitabine with oxaliplatin (GEMOX) exerts potent antiproliferative effects in human cancer cell lines, including

A Phase II Study of External Irradiation and Weekly Paclitaxel for Non-Metastatic, Unresectable Pancreatic Cancer: A Preliminary Report of RTOG Protocol 98-12
Presenter: T. Rich Affiliation: University of Virginia Type of Session: Scientific Background Unresectable/locally advanced pancreatic cancer remains a difficult disease to treat, with median survival of less than 1 year This is a new approach to the management of pancreatic cancer, using paclitaxel (Taxol) and radiation therapy to improve

Simultaneous Gemcitabine/Cisplatin and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma using a Strict GEM/RT Time Schedule. A Phase I/II Study
Presenter: T. Brunner Presenter's Affiliation: University Hospitals Erlangen, Erlangen, Germany Type of Session: Scientific Background Patients with locally advanced pancreatic cancer treated with induction chemoradiation (CRT) prior to surgery have a survival advantage as compared to patients treated with resection at diagnosis. Snady et al.